C-CAR168 CAR-T Cell Therapy for Autoimmune Diseases That Did Not Respond to Standard Treatment
Tests C-CAR168, a CAR-T cell therapy, in adults with hard-to-treat autoimmune diseases.
Plain-language title generated from the registry record
Registry title: A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Key facts
- Where
- Qingdao, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07676266, who can take part
Where in China
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Affiliated Hospital of Qingdao University
- Trial code
- NCT07676266
- Record updated
- 30 June 2026
- Original description
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapyRead full original descriptionShow less
An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Inclusion: 18 to 70 years old at the time of signing the Informed Consent Form (ICF); Diagnosed as Multiple sclerosis (MS)/Neuromyelitis Optica Spectrum Disorders (NMOSD)/Myasthenia Gravis (MG)/Systemic Lupus Erythematosus (SLE)/ Systemic Sclerosis (SSc)/ Immune-Mediated Necrotizing Myopathy (IMNM) according to recognized diagnostic criteria for at least 6 months; Prior treatment failure with standard therapy; Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.
Exclusion: Live vaccine injection within 4 weeks prior to signing the ICF; Major organ transplantation history or bone marrow/hematopoietic stem cell transplantation history; Severe cardiovascular diseases within the past 6 months prior to screening; A history of ≥ Grade 2 bleeding within 4 weeks prior to screening, or requiring long-term anticoagulants treatment; Inadequate washing time for previous treatment; Previously treated with CAR-T cell products or genetically modified T cell therapies; Malignancy history within 5 years prior to signing the ICF; Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive; Uncontrolled active infection; Severe central nervous system diseases or pathological changes; Pregnant or lactating women; Any contraindication to lumbar puncture for MS or NMOSD.